Evidence map›Paper›PMID 41798117›Full record

ReviewNeuro-oncology practice2026

Neurogenetic tumor syndromes: The current landscape of workup and treatment.

Rimas V Lukas, Ashley Cannon, Prashant Chittiboina, Harish N Vasudevan, Jaishri O Blakeley, Angela C Hirbe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rimas V LukasDepartment of Neurology, Lou & Jean Malnati Brain Tumor Institute, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-9352-5396
Ashley CannonDepartment of Clinical and Diagnostic Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Prashant ChittiboinaNational Institute of Health, Surgical Neurology Branch, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-9349-4756
Harish N VasudevanDepartments of Radiation Oncology and Neurological Surgery, University of California-San Francisco, San Francisco, California, USA.
Jaishri O BlakeleyDepartment of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
Angela C HirbeDivision of Oncology, Washington University, St Louis, Missouri, USA.

Funding

STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hui Zhang · 2018 to 2026
$21.4M
NCI NIH HHS P50 CA221747
6 · The paper itself

Abstract

Experts and generalists from numerous clinical disciplines are likely to encounter and be involved in the care of patients with neurogenetic tumor syndromes. Considerations for genetic testing are discussed. Specific conditions including neurofibromatosis type 1, neurofibromatosis type 2-related schwannomatosis, von Hippel-Lindau disease, tuberous sclerosis, Lynch syndrome, Turcot syndrome, Li-Fraumeni syndrome, and others are reviewed. A variety of targeted therapies which have received regulatory approval for these disorders are described and promising future directions for therapeutics are highlighted.

Indexed as

geneticsNF1NF2-related schwannomatosistuberous sclerosisVHL

Identifiers

PMID41798117
PMCPMC12965640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.